iPROMOMED (PRMD.ME)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | RUB bn | - | 16 | 14 | 16 | 21 | - | 47 | - |
| Operating profit | RUB bn | 7 | 17 | ||||||
| Net profit | RUB bn | - | 6 | 4 | 3 | 3 | - | 8 | - |
| EPS reported | RUB | 14.12 | 42.60 | ||||||
| Operating cashflow per share | RUB | 0.45 | 0.45 | ||||||
| Capex per share | RUB | 19.82 | 19.82 | ||||||
| FCF per share | RUB | -19.37 | -19.37 | ||||||
| Free cash flow | RUB bn | -4 | -4 | ||||||
| Net debt | RUB bn | 16 | 31 | ||||||
| Book value equity | RUB bn | 19 | 29 | ||||||
| Book value per share | RUB | 94.33 | 143.4 | ||||||
| Number of shares | m | 204.99 | 201.62 | ||||||
| DPS (TTM paid) | RUB | 1.69 | 7.06 |
Financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 25.16 | - | ||||||
| P/B LTM | x | 4.17 | 2.80 | ||||||
| P/S LTM | x | 3.76 | 1.71 | ||||||
| P/FCF LTM | x | -20.29 | -22.69 | ||||||
| EV/EBITDA LTM | x | 12.22 | 5.70 | ||||||
| EV/Sales LTM | x | 4.54 | 4.57 | ||||||
| Earnings Yield LTM | % | +3.97% | +3.70% | ||||||
| FCF Yield | % | -4.93% | -4.41% | ||||||
| Quality | |||||||||
| ROE | % | +14.97% | +17.92% | ||||||
| ROIC | % | +9.86% | +9.86% | ||||||
| Operating margin | % | +32.15% | +32.15% | ||||||
| Gross margin | % | +66.21% | +66.21% | ||||||
| FCF/Sales | % | -18.51% | -18.51% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -4.21% | +201.70% | ||||||
| Sales Growth YoY | % | +35.39% | +120.98% | ||||||
| Net Income Growth YoY | % | -1.83% | +181.33% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +23.17% | +149.25% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.43% | 0.00% | ||||||
| Dividend Growth | % | +93.70% | +317.82% | ||||||
| Payout Ratio | % | +11.97% | 0.00% | ||||||
| FCF/Debt | x | -0.19 | -0.10 | ||||||
| Net Debt/EBITDA | x | 2.12 | 2.12 | ||||||
| EBIT/Net interest | x | 2.77 | 2.77 | ||||||
| Net debt/market cap | % | +25.39% | +25.22% | ||||||
| Net debt/Equity | x | 0.84 | 1.09 | ||||||
| Gross debt/equity | x | 1.09 | 1.25 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating out of Russia, iPROMOMED functions as a pharmaceutical and biotechnology enterprise dedicated to the research, production, and commercialization of both traditional prescription medications and cutting-edge therapeutic solutions.
Similar companies
- Jiangsu Kanion Pharmaceutical Co.,Ltd.
- Saudi Pharmaceutical Industries and Medical Appliances Corporation
- Guangxi Wuzhou Zhongheng Group Co.,Ltd
- China Animal Husbandry Industry Co., Ltd.
- Northeast Pharmaceutical Group Co., Ltd.
- Dezhan Healthcare Company Limited
- Vetoquinol S.A.
- Jinghua Pharmaceutical Group Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Operating out of Russia, iPROMOMED functions as a pharmaceutical and biotechnology enterprise dedicated to the research, production, and commercialization of both traditional prescription medications and cutting-edge therapeutic solutions.
- Jiangsu Kanion Pharmaceutical Co.,Ltd.
- Saudi Pharmaceutical Industries and Medical Appliances Corporation
- Guangxi Wuzhou Zhongheng Group Co.,Ltd
- China Animal Husbandry Industry Co., Ltd.
- Northeast Pharmaceutical Group Co., Ltd.
- Dezhan Healthcare Company Limited
- Vetoquinol S.A.
- Jinghua Pharmaceutical Group Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free